David A. Siegel Genmab A/S Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Genmab A/S stock. As of the latest transaction made, Two Sigma Advisers, LP holds 615,100 shares of GMAB stock, worth $13.3 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
615,100
Previous 334,200
84.05%
Holding current value
$13.3 Million
Previous $8.4 Million
78.57%
% of portfolio
0.04%
Previous 0.02%
Shares
8 transactions
Others Institutions Holding GMAB
# of Institutions
238Shares Held
52.6MCall Options Held
10.2KPut Options Held
25.5K-
Alliancebernstein L.P. New York, NY15.1MShares$328 Million0.13% of portfolio
-
Black Rock Inc. New York, NY5.08MShares$110 Million0.0% of portfolio
-
Capital International Investors Los Angeles, CA4.42MShares$95.9 Million0.02% of portfolio
-
Harding Loevner LP Bridgewater, NJ3.07MShares$66.6 Million0.44% of portfolio
-
Wellington Management Group LLP Boston, MA2.31MShares$50 Million0.01% of portfolio
About GENMAB A/S
- Ticker GMAB
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 658,292,992
- Market Cap $14.3B
- Description
- Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...